Full View

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Y Wang, G Schmid-Bindert… - Therapeutic advances in …, 2012 - journals.sagepub.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
被引用次数：130 相关文章

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Y Wang, G Schmid-Bindert, C Zhou - Therapeutic Advances in Medical …, 2011 - cir.nii.ac.jp
抄録< jats: p> Inhibition of epidermal growth factor receptor (EGFR) has become an
important target in the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib …
[HTML] nih.gov

[HTML][HTML] Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Y Wang, G Schmid-Bindert, C Zhou - Therapeutic Advances in …, 2012 - ncbi.nlm.nih.gov
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.

Y Wang, G Schmid-Bindert… - Therapeutic Advances in …, 2012 - search.ebscohost.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Y Wang, G Schmid-Bindert… - … advances in medical …, 2012 - pubmed.ncbi.nlm.nih.gov
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.

Y Wang, G Schmid-Bindert, C Zhou - Therapeutic Advances in …, 2012 - europepmc.org
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.

Y Wang, G Schmid-Bindert, C Zhou - Therapeutic Advances in …, 2012 - europepmc.org
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …